Liquidia (NASDAQ:LQDA) Insider Sells $562,354.64 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sarah Krepp sold 7,864 shares of the business’s stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $71.51, for a total value of $562,354.64. Following the transaction, the insider directly owned 117,178 shares in the company, valued at approximately $8,379,398.78. This represents a 6.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sarah Krepp also recently made the following trade(s):

• On Thursday, June 11th, Sarah Krepp sold 24,880 shares of Liquidia stock. The stock was sold at an average price of $70.28, for a total value of $1,748,566.40.
• On Monday, June 1st, Sarah Krepp sold 276 shares of Liquidia stock. The stock was sold at an average price of $60.87, for a total transaction of $16,800.12.

Liquidia Trading Up 7.4%

LQDA stock traded up $5.28 during mid-day trading on Tuesday, reaching $76.49. 1,153,916 shares of the stock traded hands, compared to its average volume of 2,219,263. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. Liquidia Corporation has a one year low of $14.04 and a one year high of $82.96. The stock has a market capitalization of $6.80 billion, a PE ratio of 546.40 and a beta of 0.55. The business has a 50-day moving average price of $66.37 and a two-hundred day moving average price of $47.52.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11. The business had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company’s quarterly revenue was up 4187.1% on a year-over-year basis. Equities research analysts expect that Liquidia Corporation will post 3.02 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. HC Wainwright increased their price objective on shares of Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday, June 5th. BTIG Research upped their target price on Liquidia from $59.00 to $109.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Wells Fargo & Company increased their price target on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Jefferies Financial Group reissued a “buy” rating and set a $60.00 price target on shares of Liquidia in a research note on Monday, May 11th. Finally, Raymond James Financial restated a “strong-buy” rating and set a $68.00 price objective on shares of Liquidia in a report on Thursday, June 4th. Three research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $68.88.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LQDA. Farallon Capital Management LLC lifted its holdings in Liquidia by 102.1% during the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after buying an additional 4,326,876 shares in the last quarter. TCG Crossover Management LLC purchased a new stake in Liquidia in the 3rd quarter valued at about $38,887,000. MPM Bioimpact LLC grew its stake in Liquidia by 600.4% in the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after acquiring an additional 1,200,869 shares in the last quarter. Voloridge Investment Management LLC bought a new position in Liquidia in the 3rd quarter worth about $12,571,000. Finally, Bank of America Corp DE grew its stake in Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after acquiring an additional 360,372 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).